Ashim Ahuja
Neurology · Los Angeles, CANPI 1972063329
Payments from drug & device makers
What this record shows
This record is dominated by grants: $49,091 of the $51,288 with a category attached, or 95.7%. 17 manufacturers reported payments, led by Medtronic at 58.5% of the total. Reporting peaked in 2023 at $30,212 and has fallen 98.7% since, to $380 in 2025. Among neurology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 57 payments — averaging $899.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$30K
- Boston Scientific$10K
- Abbott$9K
- Teva Pharmaceuticals USA, Inc.$390
- AstraZeneca$232
- Acorda Therapeutics, Inc$228
- plus $1K from 11 others
Across 1 payment — averaging $32,718 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$33K
What the payments were for
- Grants$49,09196%
- Food & beverage$2,0434%
- Education$1540%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 2 | $30,000 |
| Boston Scientific | 2 | $10,075 |
| Abbott | 1 | $9,091 |
| Teva Pharmaceuticals USA, Inc. | 7 | $390 |
| AstraZeneca | 2 | $232 |
| Acorda Therapeutics, Inc | 2 | $228 |
| Livanova USA, Inc. | 27 | $222 |
| Alnylam Pharmaceuticals Inc. | 1 | $144 |
| Insightec,inc | 1 | $141 |
| Grifols USA, LLC | 1 | $131 |
| Eisai Inc. | 1 | $125 |
| Novartis | 1 | $117 |
| Sanofi | 1 | $112 |
| Biogen | 2 | $109 |
| UCB, Inc. | 3 | $82 |
| AbbVie | 2 | $57 |
| SK Life Science, Inc. | 1 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$51,288 in reported general payments places this provider in the 90th percentile of 1,996 neurology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 27 | $195,456 |
| RytaryCarbidopa/Levodopa | 45 | $75,885 |
| Rasagiline Mesylate | 73 | $19,381 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 280 | $14,684 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 121 | $10,606 |
| Carbidopa | 14 | $9,376 |
| Entacapone | 17 | $4,443 |
| Ropinirole ErRopinirole Hcl | 15 | $2,244 |
| AmantadineAmantadine Hcl | 36 | $2,104 |
| Mirtazapine | 53 | $1,476 |
| Quetiapine Fumarate | 60 | $1,379 |
| Donepezil Hcl | 113 | $1,160 |
| Levetiracetam | 17 | $1,055 |
| Memantine Hcl | 59 | $1,006 |
| Memantine Hcl ErMemantine Hcl | 18 | $873 |
Paid to pharmacies, not to this prescriber.
Other neurology in Los Angeles
- Perry ShiehLos Angeles$2.4M
- David LiebeskindLos Angeles$1.9M
- John SternLos Angeles$999K
- Jeffrey CummingsLos Angeles$918K
- Alan RapoportLos Angeles$808K
- Alon AvidanLos Angeles$505K
- Mark LewLos Angeles$450K
- Dawn EliashivLos Angeles$364K
- Richard LewisLos Angeles$309K
- Margaret BurnettLos Angeles$293K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.